2010
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†
Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK, Group F. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma†. Neuro-Oncology 2010, 12: 871-881. PMID: 20511192, PMCID: PMC2940677, DOI: 10.1093/neuonc/nop054.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedAntineoplastic AgentsBrain NeoplasmsCarmustineCatheters, IndwellingConvectionDecanoic AcidsDrug Administration RoutesExotoxinsFemaleGlioblastomaHumansInterleukin-13Kaplan-Meier EstimateMagnetic Resonance ImagingMaleMiddle AgedNeoplasm Recurrence, LocalPolyestersRecombinant Fusion ProteinsYoung AdultConceptsConvection-enhanced deliveryCintredekin besudotoxGliadel wafersMedian survivalTumor resectionGlioblastoma multiformeEfficacy-evaluable populationAdverse event profileHealth-related qualityPhase III evaluationTime of randomizationEvaluable populationTertiary endpointsPrimary endpointAdult patientsBaseline characteristicsFirst recurrenceOverall survivalPulmonary embolismActive comparatorTreatment armsIL13-PE38QQRIntraparenchymal catheterSurvival differencesGBM patients
2009
Primary, non-exophytic, optic nerve germ cell tumors
DiLuna ML, Two AM, Levy GH, Patel T, Huttner AJ, Duncan CC, Piepmeier JM. Primary, non-exophytic, optic nerve germ cell tumors. Journal Of Neuro-Oncology 2009, 95: 437-443. PMID: 19554263, DOI: 10.1007/s11060-009-9941-1.Peer-Reviewed Original ResearchConceptsGerm cell tumorsOptic chiasmatic gliomasMalignant mixed germ cell tumorMixed germ cell tumorOptic chiasmCell tumorsOptic chiasm tumorAdrenal axis dysfunctionSub-frontal approachChiasm gliomaChiasmatic gliomasAxis dysfunctionBiopsy confirmationProgressive symptomsVisual lossCase seriesFirst patientTreatment regimensPterional craniotomyDiabetes insipidusTissue diagnosisTissue biopsiesTumorsPatientsChiasm